Driving Reduced AIDS-associated Meningo-encephalitis Mortality (DREAMM)
AIDS-Related Opportunistic Infections, Meningo-encephalitis, Cryptococcal Meningitis
About this trial
This is an interventional health services research trial for AIDS-Related Opportunistic Infections focused on measuring HIV related Meningitis, AIDS-Related Opportunistic Infections, Advanced HIV Disease, Health Systems Strengthening, Education Programmes
Eligibility Criteria
Inclusion Criteria:
- Consecutive patients > 18 years with 1st episode of suspected meningo- encephalitis
- Known to be HIV positive or willing to undertake an HIV test
- Willing to agree to participate in the study
Exclusion Criteria:
- Patients presenting with suspected relapse of HIV-associated meningo-encephalitis
- HIV negative patients
- Pregnant or lactating patients
- Patients presenting with a known diagnosis of primary CNS Lymphoma or cerebral malaria
- COVID-19 infected patients
Patients who are HIV negative or are diagnosed with cerebral malaria on hospital admission or after initial investigation will be excluded or withdrawn from the DREAMM study.
Sites / Locations
- Hôpital Central Yaoundé
- Kamuzu Central Hospital
- Zomba Central Hospital
- Amana Hospital
- Mwananyamala Hospital
Arms of the Study
Arm 1
Other
DREAMM
4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines: Health system strengthening Delivery of a co-designed education program tailored to frontline healthcare workers Implementation of an algorithm for HIV-related meningoencephalitis Infectious diseases/AHD mentorship and laboratory capacity building